HSCT patient characteristics
| Patient characteristics . | Case cohort A . | Control cohort B . | Control cohort C . | P . | |
|---|---|---|---|---|---|
| 3/15/20 to 6/15/20 . | 12/15/19 to 3/14/20 . | 3/15/19 to 6/15/19 . | A vs B . | A vs C . | |
| Allogeneic HSCT | |||||
| Age, median (range), y | 60 (22, 77) | 62 (19, 74) | 63.5 (21, 78) | .19 | .1 |
| Sex, n (%) | .6 | .61 | |||
| Female | 30 (46.9) | 36 (52.9) | 32 (42.1) | ||
| Male | 34 (53.1) | 32 (47.1) | 44 (57.9) | ||
| Diagnosis, n (%) | .12 | .14 | |||
| Acute myeloid leukemia (AML) | 18 (28.1) | 21 (30.9) | 23 (30.3) | ||
| Acute lymphocytic leukemia | 17 (26.6) | 8 (11.8) | 13 (17.1) | ||
| Chronic myeloid leukemia | 3 (4.7) | 0 | 3 (3.9) | ||
| MDS/MPN(MDS/MPN) | 11 (17.2) | 24 (35.3) | 26 (34.2) | ||
| Therapy-related MDS/AML | 3 (4.7) | 4 (5.9) | 2 (2.6) | ||
| Other leukemia (includes chronic lymphocytic leukemia) | 2 (3.1) | 1 (1.5) | 3 (3.9) | ||
| Hodgkin lymphoma | 0 | 0 | 2 (2.6) | ||
| Non-Hodgkin lymphoma | 8 (12.5) | 8 (11.8) | 2 (2.6) | ||
| Aplastic anemia | 2 (3.1) | 1 (1.5) | 1 (1.3) | ||
| Sickle cell anemia | 0 | 1 (1.5) | 1 (1.3) | ||
| Conditioning intensity, n (%) | 1 | .3 | |||
| Myeloablative | 22 (34.4) | 23 (33.8) | 20 (26.3) | ||
| Nonmyeloablative | 41 (64.1) | 44 (64.7) | 56 (73.7) | ||
| No conditioning | 1 (1.6) | 1 (1.5) | 0 | ||
| Donor, n (%) | .37 | .88 | |||
| Matched related donor (8/8) | 15 (23.4) | 9 (13.2) | 14 (18.4) | ||
| Matched unrelated donor (8/8) | 35 (54.7) | 42 (61.8) | 44 (57.9) | ||
| 7/8 Matched unrelated donor | 2 (3.1) | 5 (7.4) | 4 (5.3) | ||
| 7/8 Matched related donor | 1 (1.6) | 0 | 1 (1.3) | ||
| Haplo | 11 (17.2) | 12 (17.6) | 12 (15.8) | ||
| Cord | 0 | 0 | 1 (1.3) | ||
| HCT-CI, median (range) | 4 (0, 10) | 4 (0, 10) | 4 (0, 12) | ||
| HCT-CI, n (%) | |||||
| 0 | 2 (3.3) | 3 (4.5) | 2 (2.7) | .21 | .09 |
| 1 | 4 (6.7) | 11 (16.4) | 10 (13.7) | ||
| 2 | 9 (15) | 9 (13.4) | 12 (16.4) | ||
| 3 | 6 (10) | 9 (13.4) | 12 (16.4) | ||
| ≥4 | 39 (65.1) | 35 (52.3) | 37 (50.6) | ||
| Autologous HSCT | |||||
| Age, median (range), y | 54 (21, 74) | 58 (19, 73) | 59.5 (19, 76) | .31 | .25 |
| Sex, n (%) | .65 | .52 | |||
| Female | 17 (43.6) | 16 (37.2) | 19 (35.2) | ||
| Male | 22 (56.4) | 27 (62.8) | 35 (64.8) | ||
| Diagnosis | .03 | .004 | |||
| Hodgkin lymphoma | 11 (28.2) | 7 (16.3) | 6 (11.1) | ||
| Non-Hodgkin lymphoma | 18 (46.2) | 17 (39.5) | 18 (33.3) | ||
| Multiple myeloma | 5 (12.8) | 18 (41.9) | 27 (50) | ||
| Solid tumors | 4 (10.3) | 1 (2.3) | 3 (5.6) | ||
| Other leukemia | 1 (2.6) | 0 | 0 | ||
| Patient characteristics . | Case cohort A . | Control cohort B . | Control cohort C . | P . | |
|---|---|---|---|---|---|
| 3/15/20 to 6/15/20 . | 12/15/19 to 3/14/20 . | 3/15/19 to 6/15/19 . | A vs B . | A vs C . | |
| Allogeneic HSCT | |||||
| Age, median (range), y | 60 (22, 77) | 62 (19, 74) | 63.5 (21, 78) | .19 | .1 |
| Sex, n (%) | .6 | .61 | |||
| Female | 30 (46.9) | 36 (52.9) | 32 (42.1) | ||
| Male | 34 (53.1) | 32 (47.1) | 44 (57.9) | ||
| Diagnosis, n (%) | .12 | .14 | |||
| Acute myeloid leukemia (AML) | 18 (28.1) | 21 (30.9) | 23 (30.3) | ||
| Acute lymphocytic leukemia | 17 (26.6) | 8 (11.8) | 13 (17.1) | ||
| Chronic myeloid leukemia | 3 (4.7) | 0 | 3 (3.9) | ||
| MDS/MPN(MDS/MPN) | 11 (17.2) | 24 (35.3) | 26 (34.2) | ||
| Therapy-related MDS/AML | 3 (4.7) | 4 (5.9) | 2 (2.6) | ||
| Other leukemia (includes chronic lymphocytic leukemia) | 2 (3.1) | 1 (1.5) | 3 (3.9) | ||
| Hodgkin lymphoma | 0 | 0 | 2 (2.6) | ||
| Non-Hodgkin lymphoma | 8 (12.5) | 8 (11.8) | 2 (2.6) | ||
| Aplastic anemia | 2 (3.1) | 1 (1.5) | 1 (1.3) | ||
| Sickle cell anemia | 0 | 1 (1.5) | 1 (1.3) | ||
| Conditioning intensity, n (%) | 1 | .3 | |||
| Myeloablative | 22 (34.4) | 23 (33.8) | 20 (26.3) | ||
| Nonmyeloablative | 41 (64.1) | 44 (64.7) | 56 (73.7) | ||
| No conditioning | 1 (1.6) | 1 (1.5) | 0 | ||
| Donor, n (%) | .37 | .88 | |||
| Matched related donor (8/8) | 15 (23.4) | 9 (13.2) | 14 (18.4) | ||
| Matched unrelated donor (8/8) | 35 (54.7) | 42 (61.8) | 44 (57.9) | ||
| 7/8 Matched unrelated donor | 2 (3.1) | 5 (7.4) | 4 (5.3) | ||
| 7/8 Matched related donor | 1 (1.6) | 0 | 1 (1.3) | ||
| Haplo | 11 (17.2) | 12 (17.6) | 12 (15.8) | ||
| Cord | 0 | 0 | 1 (1.3) | ||
| HCT-CI, median (range) | 4 (0, 10) | 4 (0, 10) | 4 (0, 12) | ||
| HCT-CI, n (%) | |||||
| 0 | 2 (3.3) | 3 (4.5) | 2 (2.7) | .21 | .09 |
| 1 | 4 (6.7) | 11 (16.4) | 10 (13.7) | ||
| 2 | 9 (15) | 9 (13.4) | 12 (16.4) | ||
| 3 | 6 (10) | 9 (13.4) | 12 (16.4) | ||
| ≥4 | 39 (65.1) | 35 (52.3) | 37 (50.6) | ||
| Autologous HSCT | |||||
| Age, median (range), y | 54 (21, 74) | 58 (19, 73) | 59.5 (19, 76) | .31 | .25 |
| Sex, n (%) | .65 | .52 | |||
| Female | 17 (43.6) | 16 (37.2) | 19 (35.2) | ||
| Male | 22 (56.4) | 27 (62.8) | 35 (64.8) | ||
| Diagnosis | .03 | .004 | |||
| Hodgkin lymphoma | 11 (28.2) | 7 (16.3) | 6 (11.1) | ||
| Non-Hodgkin lymphoma | 18 (46.2) | 17 (39.5) | 18 (33.3) | ||
| Multiple myeloma | 5 (12.8) | 18 (41.9) | 27 (50) | ||
| Solid tumors | 4 (10.3) | 1 (2.3) | 3 (5.6) | ||
| Other leukemia | 1 (2.6) | 0 | 0 | ||